iwNHL 2022

09–11 September 2022 | Barcelona, Spain

iwNHL 2022

09–11 September 2022 | Barcelona, Spain

VJHemOnc is pleased to be the official media partner for the 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL), which was held in Barcelona, Spain, on 9 – 11 September, 2022.

The workshop brought together leading international clinicians and researchers in an in-person forum to discuss the current status and recent advances in non-Hodgkin lymphoma with the aim to optimize clinical care.

Session 1: T-cell lymphoma

Laurence  de Leval
Updates in pathology & classification of gastrointestinal T-cell neoplasms
Laurence de Leval Lausanne University Hospital, Lausanne, Switzerland
Reiner  Siebert
Genetics and epigenetics of T-PLL
Reiner Siebert Ulm University, Ulm, Germany
Kate Cwynarski
AUTO4 CAR-T in T-cell lymphoma
Kate Cwynarski University College Hospital, London, United Kingdom
Steven Horwitz
What is new in the treatment of cutaneous T-cell lymphomas
Steven Horwitz Memorial Sloan Kettering Cancer Center, New York City, NY, United States

Session 2: Immunotherapy of lymphoma

Stephen Ansell
Engaging the innate & adaptive antitumor immune response in lymphoma
Stephen Ansell Mayo Clinic, Rochester, MN, United States
video coming soon
John  Kuruvilla
CAR-T and the tumor microenvironment - DLBCL as a model
John Kuruvilla Princess Margaret Cancer Centre, Toronto, Canada
video coming soon
Francisco  Hernandez-Ilizaliturri
IMiDs in combination
Francisco Hernandez-Ilizaliturri Roswell Park Cancer Institute, Buffalo, NY, United States
video coming soon
Gaël Roué
Checkpoint inhibitors
Gaël Roué Josep Carreras Leukemia Research Institute, Barcelona, Spain
video coming soon
Georg  Lenz
Salvage and bridging treatments in R/R LBCL
Georg Lenz Münster University Hospital, Münster, Germany
Kieron  Dunleavy
Double-hit lymphoma - optimizing therapy
Kieron Dunleavy George Washington University, DC, WA, United States
video coming soon

Session 4: Management of follicular lymphoma beyond first-line therapy

Jessica  Okosun
Epigenetic alterations in the development of FL
Jessica Okosun Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Anna Sureda
Transformed FL treatment options
Anna Sureda Catalan Institute of Oncology, Barcelona, Spain
David Qualls
Mechanisms of action and opportunities for synergy in FL-directed therapies
David Qualls Memorial Sloan Kettering Cancer Center, New York City, NY, United States

Session 5: T-cell therapies for lymphoma

Jeremy Abramson
CD19-CAR-T – real-world experience (commercial CARs)
Jeremy Abramson Massachusetts General Hospital Cancer Center, Boston, MA, United States
David Maloney
CD19-CAR-T – next-generation CD19-CAR-T (Humanized CARs, allo ‘off-the-shelf’ CARs etc)
David Maloney Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Maksim Mamonkin
CAR-T for T-cell lymphoid malignancies - using T-ALL as an example
Maksim Mamonkin Baylor College of Medicine, Houston, TX, United States
Catherine Bollard
Third party EBV T-cells for EBV lymphomas
Catherine Bollard Children's National Research Institute, Washington D.C., WA, United States

Session 6: Novel therapies part 1 – ADCs

Laurie  Sehn
POLARIX – Polatuzumab vedotin
Laurie Sehn BC Cancer Agency, Prince George, Canada
Carmelo Carlo-Stella
Loncastuximab tesirine
Carmelo Carlo-Stella Humanitas University, Milan, Italy
Graham Collins
ADCT-301 – Camidanlumab tesirine
Graham Collins Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
David Straus
Brentuximab vedotin
David Straus Memorial Sloan Kettering Cancer Center, New York City, NY, United States

Session 6: Novel therapies part 2 – CD20/CD3 bispecific antibodies

Arnon Kater
Redirecting T-cell activity with anti-BCMA/anti-CD3 bispecific antibodies in CLL
Arnon Kater University of Amsterdam, Amsterdam, Netherlands
Loretta Nastoupil
Mosunetuzumab
Loretta Nastoupil The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Carmelo Carlo-Stella
Glofitamab
Carmelo Carlo-Stella Humanitas University, Milan, Italy
Rajat  Bannerji
Odronextamab (REGN1979)
Rajat Bannerji Rutgers Cancer institute of New Jersey, Newark, NJ, United States

Session 8: BTK inhibitors

Loretta Nastoupil
Ibrutinib combinations
Loretta Nastoupil The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Alessandra  Tedeschi
Zanubrutinib
Alessandra Tedeschi Niguarda Cancer Center, Milan, Italy
Marek  Trněný
Acalabrutinib
Marek Trněný Charles University Hospital, Prague, Czech Republic
Anthony Mato
Pirtobrutinib (LOXO-305)
Anthony Mato Memorial Sloan Kettering Cancer Center, New York City, NY, United States

Session 9: Point/counterpoint – BiTEs versus CARs for NHL

Jason Westin
Point: CAR-T for NHL
Jason Westin MD Anderson Cancer Center, Houston, TX, United States
Marion Subklewe
Counterpoint: BiTEs for NHL
Marion Subklewe LMU Hospital Munich, Munich, Germany

iwNHL 2022 was supported by:

 

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter